Dyne Therapeutics Inc [DYN] stock prices are up 1.77% to $13.79 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DYN shares have lost -0.22% over the last week, with a monthly amount glided 0.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on December 13, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $46. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on November 26, 2024, and set its price target to $45. On October 24, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $35 on the stock. Chardan Capital Markets reiterated its Buy rating and increased its price target to $42 on May 21, 2024. Morgan Stanley initiated its recommendation with a Overweight and recommended $40 as its price target on April 30, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on February 20, 2024, and assigned it a price target of $36. In a note dated February 27, 2023, Raymond James upgraded an Strong Buy rating on this stock and boosted its target price from $16 to $27.
The stock price of Dyne Therapeutics Inc [DYN] has been fluctuating between $13.07 and $47.45 over the past year. Currently, Wall Street analysts expect the stock to reach $43.88 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $13.79 at the most recent close of the market. An investor can expect a potential return of 218.2% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -83.02%, Pretax Profit Margin comes in at -77.75%, and Net Profit Margin reading is -77.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.57 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.51 points at the first support level, and at 13.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.11, and for the 2nd resistance point, it is at 14.43.
Ratios To Look Out For
It’s worth pointing out that Dyne Therapeutics Inc [NASDAQ:DYN]’s Current Ratio is 17.02. Also, the Quick Ratio is 17.02, while the Cash Ratio stands at 12.3.
Transactions by insiders
Recent insider trading involved Beskrovnaya Oxana, Chief Scientific Officer, that happened on Feb 18 ’25 when 2598.0 shares were sold. SVP, Head of Finance & Admin., Scalzo Richard William completed a deal on Feb 18 ’25 to sell 2488.0 shares. Meanwhile, Officer Scalzo Richard William bought 2488.0 shares on Feb 18 ’25.
